Clinical trial • Oncology
MK-4716 for Non-small cell lung cancer | Advanced or metastatic solid tumors with KRAS alterations
Clinical trial of MK-4716 for Non-small cell lung cancer | Advanced or metastatic solid tumors with KRAS alterations. None/Not specified-controlled.
Overview
- Trial Therapeutic Area
- Oncology
- Trial Disease
- Non-small cell lung cancer | Advanced or metastatic solid tumors with KRAS alterations
Key dates
- Initial CTIS Submission Date
- 26-09-2025
- First CTIS Authorization Date
- 23-12-2025
Trial design
None/Not specified-controlled trial across 3 sites in Spain.
- Comparator
- None/Not specified
- Target Sample Size
- 179
Recruitment
- Planned Sample Size
- 179
- Recruitment Window Months
- 40
Geography
- Total Number Of Sites
- 3
- Total Number Of Participants
- 179
Spain
- Earliest CTIS Part Ii Submission Date
- 24-11-2025
- Latest Decision Or Authorization Date
- 05-05-2026
- Processing Time Days
- 162
- Number Of Sites
- 3
- Number Of Participants
- 29
Sites
- Site Name
- Hospital Universitari Vall D Hebron
- Department Name
- Medical Oncology
- Principal Investigator Name
- Elena Garralda Cabañas
- Principal Investigator Email
- egarralda@vhio.net
- Contact Person Name
- Elena Garralda Cabañas
- Contact Person Email
- egarralda@vhio.net
- Site Name
- Hospital Clinic De Barcelona
- Department Name
- Medical Oncology
- Principal Investigator Name
- Iván Manuel Victoria Ruiz
- Principal Investigator Email
- IVICTORI@recerca.clinic.cat
- Contact Person Name
- Iván Manuel Victoria Ruiz
- Contact Person Email
- IVICTORI@recerca.clinic.cat
- Site Name
- Hospital Universitario Fundacion Jimenez Diaz
- Department Name
- Medical Oncology
- Principal Investigator Name
- Victor Moreno Garcia
- Principal Investigator Email
- victor.moreno@startmadrid.com
- Contact Person Name
- Victor Moreno Garcia
- Contact Person Email
- victor.moreno@startmadrid.com
Sponsor
Primary sponsor
- Full Name
- Merck Sharp & Dohme LLC
- Organisation Type
- Pharmaceutical company
- Country Of Registered Address
- United States
Investigational products
- Investigational Product Name
- MK-4716
Related trials
Other published trials that may interest you.
- GDC-9545 for Locally advanced or metastatic estrogen receptor-positive breast cancer
- Abemaciclib for Stage IV lung cancer | Breast cancer
- BGB-43395 for Advanced or metastatic solid tumors | Hormone receptor positive HER2 negative breast cancer
- AZD9833 for Estrogen receptor-positive HER2-negative advanced breast cancer
- Pembrolizumab for Classical Hodgkin lymphoma | Melanoma | Solid tumours (MSI-H/dMMR) | Solid tumours (TMB-H)